Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Pre-Release VIVITROL for Opioid Dependent Inmates

This study has been completed.
National Institute on Drug Abuse (NIDA)
Alkermes, Inc.
Information provided by (Responsible Party):
Rhode Island Hospital Identifier:
First received: March 23, 2012
Last updated: October 21, 2015
Last verified: October 2015
Naltrexone is a medication that has been shown to help prevent relapse to opioid addiction and it has been reported to be clinically effective in parolee populations although it is rarely used. Recently a depot formulation with one-month duration has received FDA approval for the treatment of alcoholism and opiate dependence. This means that rather than having to take medication daily, individuals can receive one injection that lasts for approximately 30 days. The purpose of this study is to determine whether this monthly injection of naltrexone is practical and useful in the prevention of relapse to opioids and re-incarceration when administered to inmates prior to release from prison. The investigators will also monitor HIV risk behaviors to determine whether the intervention reduces risky behaviors associated with intravenous drug abuse and the spread of viruses such as HIV and hepatitis C. Volunteers will be randomized to receive an injection of depot naltrexone prior to release from prison or to contact study personnel in the community following release. Participants assigned to receive naltrexone in prison will receive 1 injection in prison, and 5 additional monthly injections for 5 months upon release. Participants assigned to contact study personnel upon release will receive all 6 injections in the community at RIH after their release from the ACI. Patients in both groups will be given identical follow up monthly for six months including measures of opiate use by self-report, and urine tests. An additional scheduled urine test will take place each month between monthly visits. There will also be a 12-month follow-up period for participants in both groups, which will consist of 2 visits, spaced 6 months apart, meaning that participants will be enrolled in the study for a total of about 18 months. All participants will be asked to complete brief questionnaires at follow-up visits to assess things such as services received, drug use, and depression.

Condition Intervention Phase
Substance-Related Disorders
Drug: naltrexone for extended release injectable suspension
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: VIVITROL® (Naltrexone for Extended Release Injectable Suspension (XR-NTX)) for Opioid Dependent Inmates Released From Prison

Resource links provided by NLM:

Further study details as provided by Rhode Island Hospital:

Primary Outcome Measures:
  • Proportion of opioid-free days [ Time Frame: 18 months ]

Enrollment: 26
Study Start Date: March 2012
Study Completion Date: August 2015
Primary Completion Date: August 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: PRE-release XR-NTX
Participants randomly assigned to the pre-release condition will receive one injection of XR-NTX 1-2 weeks prior to prison release plus up to five additional injections of XR-NTX in the community after release
Drug: naltrexone for extended release injectable suspension
VIVITROL (naltrexone for extended-release injectable suspension) is supplied as a microsphere formulation of naltrexone for suspension, at a dose of 4cc (380mg of naltrexone base), administered by intramuscular injection to the buttocks (alternating sides monthly) for six months.
Other Name: VIVITROL
Active Comparator: POST-release XR-NTX
Participant randomly assigned to the post-release group will be referred to Rhode Island Hospital to receive up to six injections of XR-NTX immediately after release from prison
Drug: naltrexone for extended release injectable suspension
VIVITROL (naltrexone for extended-release injectable suspension) is supplied as a microsphere formulation of naltrexone for suspension, at a dose of 4cc (380mg of naltrexone base), administered by intramuscular injection to the buttocks (alternating sides monthly) for six months.
Other Name: VIVITROL


Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Incarcerated adults with known release date.
  2. Meet DSM-IV criteria for current (and/or prior to incarceration) opioid dependence.
  3. Not interested in agonist (methadone, buprenorphine) treatment.
  4. Currently opioid free by history ('detoxed'), with negative urine for all opioids and no sign of opiate withdrawal after IV (or IM if no available venous access) injection of 0.8 mg naloxone.
  5. Good health by medical history, physical examination and laboratory tests.
  6. Age older than 18.
  7. Understands and signs a consent form.
  8. Able to speak and understand English.
  9. Females: not pregnant (urine hCG negative at baseline and prior to each injection), not planning conception; and planning appropriate contraception if sexually active.

Exclusion Criteria:

  1. Current drug or alcohol dependence requiring long term residential treatment that would interfere with outpatient study participation. Dependence on substances that commonly co-occur with opioid dependence (e.g. cocaine, cannabis, alcohol) that do not rise to this level of severity will not be exclusionary in order to achieve a maximally representative sample.
  2. Liver failure and/or liver function test levels greater than three times normal.
  3. Pregnancy, lactation, or failure to use adequate contraceptive methods;
  4. Active medical illness that might make participation hazardous, e.g. untreated hypertension, hepatitis with AST or ALT > 3 times upper limit of normal, unstable diabetes or heart disease. Adequately treated medical conditions are acceptable.
  5. Untreated psychiatric disorder that might make participation hazardous, e.g. untreated psychosis, bipolar disorder with mania, significant suicide risk. Adequately treated psychiatric disorders and appropriate psychotropic medications would be allowed.
  6. History of allergic reaction to naltrexone;
  7. Current chronic pain diagnosis for which opioids are required for pain relief.
  8. Obesity (BMI of 40 or greater) to reduce the likelihood of injection site reaction.
  9. Known intolerance and/or hypersensitivity to naltrexone, carboxymethylcellulose, or polylactide-co-polymers (PLG) or any other components of the diluents.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01563718

United States, Rhode Island
Rhode Island Hospital
Providence, Rhode Island, United States, 02903
Sponsors and Collaborators
Rhode Island Hospital
National Institute on Drug Abuse (NIDA)
Alkermes, Inc.
Principal Investigator: Peter D Friedmann, MD, MPH Rhode Island Hospital
  More Information

Responsible Party: Rhode Island Hospital Identifier: NCT01563718     History of Changes
Other Study ID Numbers: RIH VIVITROL -01
3R01DA024549-03S1 ( US NIH Grant/Contract Award Number )
Study First Received: March 23, 2012
Last Updated: October 21, 2015

Additional relevant MeSH terms:
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Narcotic Antagonists
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents processed this record on May 22, 2017